CARDIFF ONCOLOGY, INC. (CRDF)

Every figure this model derived for CRDF, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 44,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 34,520,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 35,592,000 AssetsCurrent 2026-06-30
current liabilities 10,797,000 LiabilitiesCurrent 2026-06-30
equity 26,532,000 StockholdersEquity 2026-06-30
ocf -40,854,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 508,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 5,225,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up CRDF on one particular measure came for.

RatioValue
current ratio3.3
current ratio reported3.3
dilution pct40.31
growth cv1.63
revenue growth-6.96
revenue growth per share-33.69
rule of 40-8327.04
sbc pct revenue1028.54

What to be careful about

What this model itself distrusts about CRDF's figures. Written by the derivation as it ran, not added afterwards.